The Cancer and Leukaemia Group (CALGB) 9343 trial (1994–1999) enrolled low-risk patients defined as those 70 years of age or older with small tumours (primarily ≤ 2 cm); Estrogen Receptor (ER)-positive were planned to receive 5 years of Tamoxifen [22]. This evidence concerns the gene ESR1 and neoplasm.